Chemist4U Builds 10,000-Person UK Waitlist for Wegovy Pill as Approval Nears in Weeks
Updated
Updated · Bloomberg · Jun 11
Chemist4U Builds 10,000-Person UK Waitlist for Wegovy Pill as Approval Nears in Weeks
3 articles · Updated · Bloomberg · Jun 11
Summary
More than 10,000 customers have joined Chemist4U’s UK waiting list for Novo Nordisk’s Wegovy pill, signaling strong demand before the drug reaches the market.
About three-quarters of people awaiting a consultation for the tablets have never used weight-loss injections, suggesting the pill could expand obesity-drug uptake beyond current shot users.
James O’Loan, Chemist4U’s chief executive, said he expects the pill to win approval within weeks, putting a near-term UK launch in view.
As thousands clamor for the new Wegovy pill, are online pharmacies leading a health revolution or a hidden safety crisis?
This pill promises to end the obesity battle, but are we just swapping a health crisis for lifelong drug dependency?
Oral Wegovy Approved in UK: Expanding Weight Loss Options for Millions Facing Obesity
Overview
On June 11, 2026, the UK approved the Wegovy pill, the country's first daily oral GLP-1 weight loss tablet. This new option gives adults with a BMI over 30, especially those who prefer not to use injections, a flexible alternative for managing overweight and obesity. The oral Wegovy pill is designed to be used alongside a reduced-calorie diet and increased physical activity, making weight management more accessible. This approval marks a significant step forward, expanding choices beyond injectables and offering a more convenient treatment path for people seeking support in their weight loss journey.